UB Paderborn / Katalog / Suche / in CDI

Surgical treatment of gastric cancer

Bratislava Medical Journal, 2015, Vol.116 (11), p.666-670

2015

Volltextzugriff (PDF)

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

The lancet oncology, 2015-07, Vol.16 (7), p.859-870

2015

Volltextzugriff (PDF)

Intestinal volvulus caused by the ingestion of magnet balls: unexpected risk in children

Rozhledy v chirurgii, 2015-05, Vol.94 (5), p.204

2015

Volltextzugriff (PDF)

The Influence of Palliative Chemotherapy on the Quality of Life of Patients with Gastric Cancer

Klinická onkologie, 2016, Vol.29 (4), p.279-286

2016

Volltextzugriff (PDF)

Predictive and prognostic factors of gastric cancer

Rozhledy v chirurgii, 2016, Vol.95 (4), p.156

2016

Volltextzugriff (PDF)

Thyroid carcinoma, ten-years file

Rozhledy v chirurgii, 2016, Vol.95 (11), p.394

2016

Volltextzugriff (PDF)

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

The Lancet (British edition), 2013-03, Vol.381 (9869), p.805-816

2013

Volltextzugriff (PDF)

Adsorption of linear aliphatic α,ω-dithiols on plasmonic metal nanoparticles: a structural study based on surface-enhanced Raman spectra

Physical chemistry chemical physics : PCCP, 2014-06, Vol.16 (23), p.11461-11470

2014

Volltextzugriff (PDF)

Wear mechanism in automotive brake materials, wear debris and its potential environmental impact

Wear, 2009-06, Vol.267 (5), p.807-817

2009

Volltextzugriff (PDF)

2337 Ramucirumab (RAM) as a second-line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib in the randomized phase III REACH study: Analysis of alpha-fetoprotein (AFP) kinetics during treatment

European journal of cancer (1990), 2015-09, Vol.51, p.S446-S446

2015

Volltextzugriff (PDF)

Ramucirumab as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Analysis of Reach Patients by Albumin-Bilirubin (ALBI) Grade

Journal of hepatology, 2016, Vol.64 (2), p.S693-S694

2016

Volltextzugriff (PDF)

338. Comparing characteristics and survival outcomes of adolescent and young adults to mature patients with colorectal cancer

European journal of surgical oncology, 2016-09, Vol.42 (9), p.S152-S152

2016

Volltextzugriff (PDF)

INCIDENCE AND OUTCOME OF PRIMARY EXTRANODAL FOLLICULAR LYMPHOMAS. ANALYSIS FROM THE CZECH LYMPHOMA STUDY GROUP (CLSG) REGISTRY

Hematological oncology, 2017-06, Vol.35 (S2), p.381-382

2017

Volltextzugriff (PDF)

Adsorption of linear aliphatic α,ω-dithiols on plasmonic metal nanoparticles: a structural study based on surface-enhanced Raman spectraElectronic supplementary information (ESI) available: Table with the wavenumbers and assignments of the main bands observed in Raman and SERS spectra of DT8 (Table S1). Calculation of tilt angles of dithiols adsorbed on Ag and Au (the used metal) NPs (Table S2). See DOI: 10.1039/c4cp00424h

2014-05

Volltextzugriff (PDF)

Validation of data on smoking and alcohol consumption in the population

Časopis lékařů českých, 1987-10, Vol.126 (42), p.1305

1987

Volltextzugriff (PDF)

European regulation on orphan medicinal products: 10 years of experience and future perspectives

Nature reviews. Drug discovery, 2011-05, Vol.10 (5), p.341-349

2011

Volltextzugriff (PDF)

SAT-076 - Ramucirumab as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Analysis of Reach Patients by Albumin-Bilirubin (ALBI) Grade

Journal of hepatology, 2016, Vol.64 (2), p.S693-S694

2016

Volltextzugriff (PDF)

O-005 Ramucirumab (RAM) as second-Line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib: comprehensive results from the randomized phase III REACH study

Annals of oncology, 2015-06, Vol.26, p.iv109

2015

Volltextzugriff (PDF)

Cytostatic and immunomobilizing activities of polymer-bound drugs: experimental and first clinical data

Journal of controlled release, 2003-08, Vol.91 (1), p.1-16

2003

Volltextzugriff (PDF)

LBA16RAMUCIRUMAB (RAM) AS SECOND-LINE TREATMENT IN PATIENTS (PTS) WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) FOLLOWING FIRST-LINE THERAPY WITH SORAFENIB: RESULTS FROM THE RANDOMIZED PHASE III REACH STUDY

Annals of oncology, 2014-09, Vol.25 (suppl_4)

2014

Volltextzugriff (PDF)

Ramucirumab (Ram) As Second-Line Treatment in Patients (Pts) with Advanced Hepatocellular Carcinoma (Hcc) Following First-Line Therapy with Sorafenib: Results from the Randomized Phase III Reach Study

Annals of oncology, 2014-09, Vol.25, p.v1

2014

Volltextzugriff (PDF)

Acquired and specific immunological mechanisms co-responsible for efficacy of polymer-bound drugs

Journal of controlled release, 2002-01, Vol.78 (1), p.97-114

2002

Volltextzugriff (PDF)

Favorable Outcome of High-Risk Mediastinal Diffuse Large B-Cell Lymphoma (DLBCL) after Dose-Intensive Chemotherapy, Rituximab and Autologous Transplant (ASCT)

Blood, 2004-11, Vol.104 (11), p.1322-1322

2004

Volltextzugriff (PDF)

Drug-HPMA-HuIg conjugates effective against human solid cancer

Advances in experimental medicine and biology, 2003, Vol.519, p.125

2003

Volltextzugriff (PDF)

Wear mechanism in automotive brake materials, wear debris and its potential environmental impact

Wear, 2009, Vol.267 (2), p.807-817

2009

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Surgical treatment of gastric cancer

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

Intestinal volvulus caused by the ingestion of magnet balls: unexpected risk in children

The Influence of Palliative Chemotherapy on the Quality of Life of Patients with Gastric Cancer

Predictive and prognostic factors of gastric cancer

Thyroid carcinoma, ten-years file

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

Adsorption of linear aliphatic α,ω-dithiols on plasmonic metal nanoparticles: a structural study based on surface-enhanced Raman spectra

Wear mechanism in automotive brake materials, wear debris and its potential environmental impact

2337 Ramucirumab (RAM) as a second-line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib in the randomized phase III REACH study: Analysis of alpha-fetoprotein (AFP) kinetics during treatment

Ramucirumab as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Analysis of Reach Patients by Albumin-Bilirubin (ALBI) Grade

338. Comparing characteristics and survival outcomes of adolescent and young adults to mature patients with colorectal cancer

INCIDENCE AND OUTCOME OF PRIMARY EXTRANODAL FOLLICULAR LYMPHOMAS. ANALYSIS FROM THE CZECH LYMPHOMA STUDY GROUP (CLSG) REGISTRY

Validation of data on smoking and alcohol consumption in the population

European regulation on orphan medicinal products: 10 years of experience and future perspectives

SAT-076 - Ramucirumab as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Analysis of Reach Patients by Albumin-Bilirubin (ALBI) Grade

O-005 Ramucirumab (RAM) as second-Line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib: comprehensive results from the randomized phase III REACH study

Cytostatic and immunomobilizing activities of polymer-bound drugs: experimental and first clinical data

LBA16RAMUCIRUMAB (RAM) AS SECOND-LINE TREATMENT IN PATIENTS (PTS) WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) FOLLOWING FIRST-LINE THERAPY WITH SORAFENIB: RESULTS FROM THE RANDOMIZED PHASE III REACH STUDY

Ramucirumab (Ram) As Second-Line Treatment in Patients (Pts) with Advanced Hepatocellular Carcinoma (Hcc) Following First-Line Therapy with Sorafenib: Results from the Randomized Phase III Reach Study

Acquired and specific immunological mechanisms co-responsible for efficacy of polymer-bound drugs

Favorable Outcome of High-Risk Mediastinal Diffuse Large B-Cell Lymphoma (DLBCL) after Dose-Intensive Chemotherapy, Rituximab and Autologous Transplant (ASCT)

Drug-HPMA-HuIg conjugates effective against human solid cancer

Wear mechanism in automotive brake materials, wear debris and its potential environmental impact

Suchergebnisse filtern